The potential role of contrast-enhanced mammography in downgrading BI-RADS 4 lesions: A balanced perspective
- 27 September 2023
- journal article
- letter
- Published by Elsevier in European Journal of Radiology
- Vol. 168, 111111
Abstract
No abstract availableFunding Information
- BARD
This publication has 7 references indexed in Scilit:
- Estimated Lifetime Gained With Cancer Screening TestsJAMA Internal Medicine, 2023
- BIRADS 4 – Is it possible to downgrade lesions that do not enhance on recombinant contrast-enhanced mammography images?European Journal of Radiology, 2023
- Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary BiopsyClinical Cancer Research, 2021
- Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: A systematic review and meta-analysisThe Breast, 2020
- Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and TestsJAMA Internal Medicine, 2015
- Breast MRI BI-RADS Assessments and Abnormal Interpretation Rates by Clinical Indication in US Community PracticesAcademic Radiology, 2014
- Reconsidering the Criteria for Evaluating Proposed Screening Programs: Reflections From 4 Current and Former Members of the U.S. Preventive Services Task ForceEpidemiologic Reviews, 2011